Treatment progress of relapsed/refractory follicular lymphoma
10.3760/cma.j.cn115356-20230111-00014
- VernacularTitle:复发难治滤泡淋巴瘤治疗进展
- Author:
Zhijuan LIN
1
;
Bing XU
Author Information
1. 厦门大学附属第一医院血液科，厦门 361003
- Keywords:
Lymphoma, follicular;
Recurrence;
Refractory;
Molecular targeted therapy;
Antibodies, bispecific;
Chimeric antigen receptor T-cell
- From:
Journal of Leukemia & Lymphoma
2023;32(2):79-81
- CountryChina
- Language:Chinese
-
Abstract:
Follicular lymphoma (FL) is the most common indolent B-cell lymphoma. The outcome of relapsed/refractory FL patients after multi-therapy is poor. The 64th American Society of Hematology annual meeting in 2022 announced the latest updates on relapsed/refractory FL, including targeted therapy, bio-specific antibodies and chimeric antigen receptor T-cell. This review provides an overview of these updates.
